Drug intelligence / Profile preview

Prevenar 13 + Synflorix

Development stage: Preclinical
Lead developer: GSK
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A combination pneumococcal conjugate vaccine schedule being investigated in clinical trials, particularly for high-risk Indigenous infants. This schedule involves administering **Synflorix** (PHiD-CV10) at 1, 2, and 4 months of age, followed by **Prevenar 13** (PCV13) at 6 months of age. The schedule aims to provide earlier and broader protection against pneumococcal disease and related pathogens compared to current single vaccine schedules.

Brand names: Prevenar 13 + Synflorix
Other names: PCV13 + PHiD-CV10PCV13 + PCV10

Targets

PD (Protein D)CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on Prevenar 13 + Synflorix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prevenar 13 + Synflorix.

Explore the full profile